AR075247A1 - Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica - Google Patents
Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeuticaInfo
- Publication number
- AR075247A1 AR075247A1 ARP100100315A ARP100100315A AR075247A1 AR 075247 A1 AR075247 A1 AR 075247A1 AR P100100315 A ARP100100315 A AR P100100315A AR P100100315 A ARP100100315 A AR P100100315A AR 075247 A1 AR075247 A1 AR 075247A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- cycloalkyl
- alkyl
- cycle
- alkylene
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- -1 cinolinyl Chemical group 0.000 abstract 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 4
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 4
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004306 triazinyl group Chemical group 0.000 abstract 3
- 101100134927 Gallus gallus COR8 gene Proteins 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000002541 furyl group Chemical group 0.000 abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 abstract 2
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 2
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 abstract 2
- 125000002971 oxazolyl group Chemical group 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000335 thiazolyl group Chemical group 0.000 abstract 2
- 125000001544 thienyl group Chemical group 0.000 abstract 2
- 125000004001 thioalkyl group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 abstract 1
- HEAHLTGDUHXTTO-UHFFFAOYSA-N 1,3-thiazolidine 1,1-dioxide Chemical compound O=S1(=O)CCNC1 HEAHLTGDUHXTTO-UHFFFAOYSA-N 0.000 abstract 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 abstract 1
- FBXGQDUVJBKEAJ-UHFFFAOYSA-N 4h-oxazin-3-one Chemical compound O=C1CC=CON1 FBXGQDUVJBKEAJ-UHFFFAOYSA-N 0.000 abstract 1
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 abstract 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 abstract 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003951 lactams Chemical class 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- LKZKGRRDUWVNSR-UHFFFAOYSA-N oxazepin-3-one Chemical compound O=C1NOC=CC=C1 LKZKGRRDUWVNSR-UHFFFAOYSA-N 0.000 abstract 1
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- TVQOEGVBMRCMFR-UHFFFAOYSA-N thiadiazinane Chemical compound C1CNNSC1 TVQOEGVBMRCMFR-UHFFFAOYSA-N 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composicion farmacéutica, proceso de preparacion y uso como inhibidores de la enzima FAAH. Reivindicacion 1: Compuesto que responde a la formula (1) en la que R2 representa un átomo de hidrogeno, de fluor o un grupo hidroxilo, ciano, trifluorometilo, alquilo C1-6, alcoxi C1-6, NR8R9; rn, n, o y p representan, independientemente entre sí, un numero entero igual a 0, 1, 2 o 3; A representa un enlace covalente o un grupo alquileno C1-8; R1 representa un grupo R5 opcionalmente sustituido por uno o varios grupos R6 y/o R7; R5 representa un grupo elegido entre un fenilo, piridinilo, piridazinilo, pirimidinilo, pirazinilo, triazinilo, naftalenilo, quinolinilo, isoquinolinilo, ftalazinilo, quinazolinilo, quinoxalinilo, cinolinilo, naftiridinilo; R6 representa un átomo de halogeno, un grupo ciano, -CH2CN, nitro, hidroxilo, alquilo C1-6, alcoxi C1-6, tioalquilo C1-6, haloalquilo C1-6, haloalcoxi C1-6, halotioalquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, cicloalquil C3-7-alquilen C1-3-O-, NR8R9, NR8COR9, NR8CO2R9, NR8SO2R9, NR8SO2NR8R9, COR8, CO2R8, CONR8R9, SO2R8, SO2NR8R9 u -O-alquilen C1-3-O-; R7 representa un grupo elegido entre un: furanilo, pirrolilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, imidazolilo, pirazolilo, oxadiazol, tiadiazol, fenilo, piridinilo, piridazinilo, pirimidinilo, pirazinilo, triazina, naftalenilo, quinolinilo, isoquinolinilo, ftalazinilo, quinazolinilo, quinoxalinilo, cinnolinilo, naftiridinilo, imidazopirimidinilo, tienopirimidinilo, benzofuranilo, benzotienilo, bencimidazolilo, benzoxazolilo, bencisoxazolilo, benzotiazolilo, bencisotiazolilo, indolilo, isoindolilo, indazolilo, pirrolopiridinilo, furopiridinilo, tienopiridinilo, imidazopiridinilo, pirazolopiridinilo, oxazolopiridinilo, isoxazolopiridinilo, tiazolopiridinilo, feniloxi, benciloxi, pirimidinoxi; pudiendo estar el o los grupos R7 sustituidos por uno o varios grupos R6 idénticos o diferentes entre sí; R3 representa un átomo de hidrogeno, de fluor, un grupo alquilo C1-6 o un grupo trifluorometilo; R4 representa un grupo elegido entre un: furanilo, pirrolilo, tienilo, tiazolilo, isotiazolilo, oxazolilo, isoxazolilo, pirazolilo, oxadiazolilo, tiadiazolilo, imidazolilo, triazolilo, tetrazolilo; estando este grupo opcionalmente sustituido por uno o varios sustituyentes elegidos entre un átomo de halogeno, un grupo alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, haloalcoxi C1-6, ciano, NR8R9, NR8COR9, NR8CO2R9, NR8SO2R9, NR8SO2NR8R9, COR8, CO2R8, CONR8R9, CON(R8)alquilen C1-3-NR10R11, SO2R8, SO2NR8R9 u -O-alquilen C1-3-O-; fenilo, feniloxi, benciloxi, piridinilo, pirazinilo, piridazinilo, triazinilo o pirimidinilo; pudiendo estar los grupos fenilo, feniloxi, benciloxi, piridinilo, pirazinilo, piridazinilo, triazinilo y pirimidinilo sustituidos por uno o varios sustituyentes elegidos entre un átomo de halogeno, un grupo ciano, nitro, alquilo C1-6, alcoxi C1-6, tioalquilo C1-6, haloalquilo C1-6, haloalcoxi C1-6, halotioalquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3; R8 y R9 representan, independientemente entre sí, un átomo de hidrogeno o un grupo alquilo C1-6, o forman con el o los átomos a los que están unidos, en el caso de NR8R9, un ciclo elegido entre los ciclos: azetidina, pirrolidina, piperidina, morfolina, tiomorfolina, azepina, oxazepina o piperazina, estando este ciclo opcionalmente sustituido por un grupo alquilo C1-6 o bencilo; en el caso de NR8COR9, un ciclo lactama; en el caso de NR8CO2R9, un ciclo oxazolidinona, oxazinona u oxazepinona; en el caso de NR8SO2R9, un ciclo sultame; en el caso de NR8SO2NR8R9, un ciclo dioxido de tiazolidina o dioxido de tiadiazinano; R10 y R11 representan, independientemente entre sí, un átomo de hidrogeno o un grupo alquilo C1-6 en el estado de base o de sal de adicion a un ácido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0900493A FR2941696B1 (fr) | 2009-02-05 | 2009-02-05 | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075247A1 true AR075247A1 (es) | 2011-03-16 |
Family
ID=41037747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100315A AR075247A1 (es) | 2009-02-05 | 2010-02-05 | Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8889702B2 (es) |
| EP (1) | EP2393809B1 (es) |
| JP (1) | JP5586632B2 (es) |
| KR (1) | KR20110117215A (es) |
| CN (1) | CN102369200B (es) |
| AR (1) | AR075247A1 (es) |
| AU (1) | AU2010212235B2 (es) |
| BR (1) | BRPI1007456A2 (es) |
| CA (1) | CA2751481C (es) |
| CO (1) | CO6362007A2 (es) |
| EA (1) | EA201171000A1 (es) |
| FR (1) | FR2941696B1 (es) |
| IL (1) | IL214390A0 (es) |
| MA (1) | MA33104B1 (es) |
| MX (1) | MX2011008308A (es) |
| SG (1) | SG173557A1 (es) |
| TN (1) | TN2011000331A1 (es) |
| TW (1) | TW201039823A (es) |
| UY (1) | UY32423A (es) |
| WO (1) | WO2010089510A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
| WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
| SG11201405056UA (en) | 2012-03-02 | 2014-09-26 | Genentech Inc | Amido spirocyclic amide and sulfonamide derivatives |
| WO2014054053A1 (en) * | 2012-10-03 | 2014-04-10 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| ES2699354T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| JP6718889B2 (ja) | 2015-06-19 | 2020-07-08 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物および組成物 |
| WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| CN107787323B (zh) | 2015-06-19 | 2020-09-01 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| US20190083460A1 (en) * | 2016-03-16 | 2019-03-21 | Zeno Royalties & Milestones, LLC | Analgesic compounds |
| RU2744988C2 (ru) | 2016-06-14 | 2021-03-17 | Новартис Аг | Соединения и композиции для подавления активности shp2 |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| AU2018207464B2 (en) | 2017-01-10 | 2020-05-14 | Novartis Ag | Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor |
| PL3595665T3 (pl) | 2017-03-13 | 2025-01-13 | Lundbeck La Jolla Research Center, Inc. | Podwójne inhibitory magl i faah |
| KR20200046061A (ko) | 2017-08-29 | 2020-05-06 | 룬드벡 라 졸라 리서치 센터 인코포레이티드 | 스피로사이클 화합물 및 이를 제조하고 사용하는 방법 |
| KR102833434B1 (ko) * | 2018-09-27 | 2025-07-15 | 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디. | 인돌아민-2,3-디옥시게나아제 억제 활성을 갖는 퀴놀린 유도체 |
| CA3250023A1 (en) | 2022-05-04 | 2023-11-09 | H. Lundbeck A/S | CRYSTALLINE FORM OF 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-YL (S)-1-(PYRIDAZINE-3-YLCARBAMOYL)-6 AZASPIRO[2,5]OCTANE-6-CARBOXYLATE AS A MONOACYLGLYCEROL LIPASE INHIBITOR |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992022550A1 (en) | 1991-06-19 | 1992-12-23 | Pfizer Inc. | Azaspiro quinolone antibacterial agents |
| WO1998006720A1 (fr) | 1996-08-09 | 1998-02-19 | Eisai Co., Ltd. | Derives de benzopiperidine |
| CN1210265C (zh) | 1998-02-19 | 2005-07-13 | 卫材株式会社 | 酞嗪衍生物和勃起障碍的治疗剂 |
| FR2816938B1 (fr) | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| JP2003246780A (ja) | 2001-12-17 | 2003-09-02 | Eisai Co Ltd | 含窒素芳香環化合物の製造方法 |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| FR2843964B1 (fr) * | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
| CA2501506C (en) * | 2002-10-07 | 2014-02-11 | Daniele Piomelli | Modulation of anxiety through blockade of anandamide hydrolysis |
| FR2854633B1 (fr) * | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866885B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique |
| FR2885364B1 (fr) * | 2005-05-03 | 2007-06-29 | Sanofi Aventis Sa | Derives d'alkyl-, alkenyl-et alkynylcarbamates, leur preparation et leur application en therapeutique |
| WO2008013834A1 (en) | 2006-07-24 | 2008-01-31 | Gilead Sciences, Inc., | Bisfuranyl protease inhibitors |
| TW200831080A (en) * | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| FR2934265B1 (fr) * | 2008-07-23 | 2010-07-30 | Sanofi Aventis | Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique |
| US20100113465A1 (en) * | 2008-10-30 | 2010-05-06 | Pfizer Inc. | 7-azaspiro[3.5]nonane-7-carboxamide compounds |
-
2009
- 2009-02-05 FR FR0900493A patent/FR2941696B1/fr not_active Expired - Fee Related
-
2010
- 2010-02-04 AU AU2010212235A patent/AU2010212235B2/en not_active Ceased
- 2010-02-04 EA EA201171000A patent/EA201171000A1/ru unknown
- 2010-02-04 JP JP2011548754A patent/JP5586632B2/ja not_active Expired - Fee Related
- 2010-02-04 SG SG2011056462A patent/SG173557A1/en unknown
- 2010-02-04 CN CN201080014506.8A patent/CN102369200B/zh not_active Expired - Fee Related
- 2010-02-04 BR BRPI1007456-2A patent/BRPI1007456A2/pt not_active IP Right Cessation
- 2010-02-04 MX MX2011008308A patent/MX2011008308A/es unknown
- 2010-02-04 WO PCT/FR2010/050183 patent/WO2010089510A2/fr not_active Ceased
- 2010-02-04 KR KR1020117020496A patent/KR20110117215A/ko not_active Withdrawn
- 2010-02-04 EP EP10708283.6A patent/EP2393809B1/fr active Active
- 2010-02-04 US US13/145,926 patent/US8889702B2/en not_active Expired - Fee Related
- 2010-02-04 CA CA2751481A patent/CA2751481C/fr not_active Expired - Fee Related
- 2010-02-04 MA MA34149A patent/MA33104B1/fr unknown
- 2010-02-05 TW TW099103578A patent/TW201039823A/zh unknown
- 2010-02-05 AR ARP100100315A patent/AR075247A1/es not_active Application Discontinuation
- 2010-02-05 UY UY0001032423A patent/UY32423A/es not_active Application Discontinuation
-
2011
- 2011-07-05 TN TN2011000331A patent/TN2011000331A1/fr unknown
- 2011-08-01 IL IL214390A patent/IL214390A0/en unknown
- 2011-08-05 CO CO11099134A patent/CO6362007A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL214390A0 (en) | 2011-09-27 |
| BRPI1007456A2 (pt) | 2019-04-16 |
| FR2941696B1 (fr) | 2011-04-15 |
| UY32423A (es) | 2010-09-30 |
| JP5586632B2 (ja) | 2014-09-10 |
| EA201171000A1 (ru) | 2012-02-28 |
| WO2010089510A3 (fr) | 2010-09-30 |
| SG173557A1 (en) | 2011-09-29 |
| TW201039823A (en) | 2010-11-16 |
| JP2012516881A (ja) | 2012-07-26 |
| AU2010212235B2 (en) | 2016-06-09 |
| US20110319381A1 (en) | 2011-12-29 |
| CA2751481A1 (fr) | 2010-08-12 |
| CA2751481C (fr) | 2017-05-23 |
| TN2011000331A1 (fr) | 2013-03-27 |
| FR2941696A1 (fr) | 2010-08-06 |
| WO2010089510A2 (fr) | 2010-08-12 |
| EP2393809B1 (fr) | 2014-04-30 |
| CN102369200B (zh) | 2015-05-20 |
| MX2011008308A (es) | 2011-11-02 |
| MA33104B1 (fr) | 2012-03-01 |
| CN102369200A (zh) | 2012-03-07 |
| US8889702B2 (en) | 2014-11-18 |
| KR20110117215A (ko) | 2011-10-26 |
| CO6362007A2 (es) | 2012-01-20 |
| EP2393809A2 (fr) | 2011-12-14 |
| AU2010212235A1 (en) | 2011-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075247A1 (es) | Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica | |
| AR072593A1 (es) | DERIVADOS DE ALQUILTIAZOLES, SU PREPARACIoN, COMPOSICIONES FARMACEUTICA QUE LOS CONTIENEN Y SU USO COMO INHIBIDORES DE LA ENZIMA FAAH | |
| AR076562A1 (es) | Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica | |
| AR076563A1 (es) | Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparacion y su apli-cacion en terapeutica | |
| AR074119A1 (es) | Derivados de carbamatos de alquil-heterociclos, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en el tratamiento de enfermedades neurologicas,infecciosas y gastrointestinales, entre otras. | |
| AR076561A1 (es) | Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica | |
| AR044178A1 (es) | Derivados de piperidinil- y piperazinil-alquilcarbamatos, su preparacion y su aplicacion en terapeutica | |
| PE20091974A1 (es) | Derivados de indazoles sustituidos con fenil o piridinilo | |
| AR067444A1 (es) | Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas | |
| UY30603A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica | |
| NI200800036A (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| AR086881A1 (es) | Derivados de picolinamida como agonistas del receptor cb2 | |
| BRPI0612888A8 (pt) | anilino-piridinotriazinas cíclicas | |
| AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
| PE20091433A1 (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177 | |
| AR047818A1 (es) | Derivados de piperidinilalquilcarbamatos, su preparacion y su aplicacion en terapeutica | |
| AR088625A1 (es) | Derivados de aril-quinolina | |
| PE20090595A1 (es) | Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1 | |
| CO6351734A2 (es) | Compuestos de amida utiles en terapia | |
| CO6251235A2 (es) | Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica | |
| AR066605A1 (es) | Derivados de heteroarilamida pirimidona | |
| AR047384A1 (es) | Derivados de tipo ariloxialquilcarbamatos, su preparacion y su aplicacion en terapeutica | |
| AR042746A1 (es) | Derivados de arilalquilcarbamatos, su preparacion y su aplicacion en terapeutica. | |
| AR070438A1 (es) | Derivados de 3- aminoalquil -1,3- dihidro -2h indol-2- ona su preparacion y su aplicacion en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |